News Releases

Each brings significant experience in strategic marketing of rare disease therapeutics and commercial operations BOSTON , Oct. 19, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule th...

Final enrollment of 31 adult and pediatric patients exceeds initial target of 18-28 patients Top-line data expected in 4Q 2022; U.S. NDA filing anticipated in 1Q 2023 BOSTON , Oct. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and...

BOSTON , Oct. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on September 30, 2021 , the Compensation Comm...

BOSTON , Sept. 15, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will present ...

Expanded role further supports corporate growth, late-stage clinical development and preparations for potential commercialization of mavorixafor in WHIM syndrome and beyond BOSTON , Sept. 08, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discov...

BOSTON , Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on August 31, 2021 , the Compensation Commit...

BOSTON , Sept. 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will conduct ...

BOSTON , Aug. 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases of the immune system resulting from dysfunction of the CXCR4 pathway, today announced that management will participa...

Twenty-three patients now enrolled in ongoing pivotal Phase 3 trial in WHIM syndrome, surpassing minimum needed for primary endpoint analyses; enrollment to complete in 3Q21 with top-line data expected in 4Q22 Minimum number of patients now enrolled to determine optimal dosing of...

BOSTON , July 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the s...

BOSTON , July 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on June 30, 2021 , the Compensation Committee...

Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus ibrutinib therapy in double-mutation Waldenström’s patients; meaningful increases in hemoglobin levels suggest reduction in cancer burden in bone marrow At 6 months, patients ...

Poster presentation by lead author Dr. Steven Treon available on the EHA website  Friday, June 11, 2021 at 9:00 am CET / 3:00 am ET Conference call and webcast with poster co-author Dr. Christian Buske to take place on  Friday, June 11, 2021 at 7:00 am ET BOSTON , May 26, 2021 (G...

BOSTON , May 17, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will participate in a fireside chat ...

Initial data from first cohort of patients indicate mavorixafor plus ibrutinib to be well tolerated, with encouraging decreases in serum IgM observed These and additional preliminary Phase 1b data to be presented in an e-Poster on June 11 at the 2021 European Hematology Associati...

Company continues to make significant clinical progress with lead candidate mavorixafor across multiple rare disease indications Enrollment update on Phase 3 WHIM trial expected in mid-2021 Initial data from ongoing Phase 1b trial in Waldenström’s macroglobulinemia to be presente...

BOSTON , May 04, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on April 30, 2021 , the Compensation Committee...

BOSTON , April 22, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that it will report its financial results for the ...

BOSTON , April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview ...

BOSTON , April 01, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on March 31, 2021 , the Compensation Committ...